Form 4: Medpace Holdings CEO August J. Troendle Sells 100,000 Shares

Medpace Holdings CEO August J. Troendle, through Medpace Investors, LLC, sold 100,000 shares of common stock in two days at weighted average prices of $401.88 and $404.13.

Summary

• August J. Troendle, CEO of Medpace Holdings, Inc., reported the sale of 100,000 shares of common stock.
• The sales occurred on February 27 and 28, 2024.
• The shares were sold indirectly through Medpace Investors, LLC (MPI), of which Troendle is the sole manager and controlling unit holder.
• On February 27, 2024, 50,000 shares were sold at a weighted average price of $401.88, in transactions ranging from $398.84 to $404.17.
• On February 28, 2024, another 50,000 shares were sold at a weighted average price of $404.13, in transactions ranging from $400.105 to $407.27.
• Following these transactions, Troendle indirectly beneficially owns 5,133,019 shares through MPI and directly owns 806,643 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The Form 4 filing simply reports the sale of shares by the CEO, which is a routine event. The sales were conducted under a pre-arranged trading plan, mitigating concerns about negative insider sentiment.

Management Comments

• The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

Sales by company insiders are a common occurrence, but investors often monitor these transactions for signals about management's confidence in the company's future prospects. It's important to consider the size of the sale relative to the insider's total holdings and the context of the company's performance and outlook.

Comparison to Industry Standards

• Comparing Troendle's transactions to other CEOs in the CRO (Contract Research Organization) industry, it's important to consider the percentage of total holdings sold.
• For example, if the CEO of ICON plc (ICLR) or PPD (now part of Thermo Fisher Scientific) were to sell a similar percentage of their holdings, it would provide a better benchmark.
• Generally, sales representing a small fraction of total holdings are viewed as less significant than larger sales.

Stakeholder Impact

• The sale of shares by the CEO could potentially create short-term selling pressure on the stock.
• However, the impact is likely to be minimal given the relatively small size of the sale compared to the total outstanding shares and the pre-planned nature of the transactions.

Key Dates